Apellis Pharmaceuticals, Inc.

Total Valuation

Apellis Pharmaceuticals, Inc. carries a market capitalization of 5.25B, placing it among publicly traded companies globally. Its enterprise value stands at 5.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Apellis Pharmaceuticals, Inc. currently has 127.92M shares outstanding.

Valuation Ratios

Apellis Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 38.25. The price-to-sales ratio is 4.61, and the price-to-book ratio stands at -1.70.

Enterprise Valuation

On an enterprise value basis, Apellis Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 31.02 and an EV/FCF ratio of 63.75. The EV/Sales ratio of 4.68 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 31.28 provides insight into valuation relative to core operating earnings.

Financial Position

Apellis Pharmaceuticals, Inc. maintains a current ratio of 3.63, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 114.66, indicating elevated leverage, while an interest coverage ratio of 3.82 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Apellis Pharmaceuticals, Inc. has paid 1.88M in income taxes, reflecting an effective tax rate of 1.39.

Stock Price Statistics

Apellis Pharmaceuticals, Inc.'s stock has gained approximately 121.66397% over the past 52 weeks. The 50-day moving average sits at 33.60, while the 200-day moving average is 26.15.

Income Statement

Over the trailing twelve months, Apellis Pharmaceuticals, Inc. generated 1.11B in revenue and converted that into 133.27M in net income, yielding earnings per share of 1.03. EBITDA reached 166.63M, while operating income came in at 165.22M.

Balance Sheet

Apellis Pharmaceuticals, Inc. holds 405.21M in cash and equivalents against 475.76M in total debt, resulting in a net debt position of 50.78M. Total book value stands at -2.99B, with working capital of 744.57M providing operational flexibility.

Cash Flow

Apellis Pharmaceuticals, Inc. produced 37.77M in operating cash flow over the past twelve months. After subtracting -305,000.00 in capital expenditures, free cash flow totaled 37.47M - equivalent to 0.30 per share.

Margins

Apellis Pharmaceuticals, Inc. operates with a gross margin of 90.19, reflecting its pricing power and cost economics. The operating margin of 14.95 and net profit margin of 12.06 provide insight into operational efficiency.

Dividends & Yields

Scores

Apellis Pharmaceuticals, Inc. posts an Altman Z-Score of 3.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.